Jubilant Life Sciences' arm to receive $147.5 million financing package from IFC

Jubilant Life Sciences - wholly owned subsidiary - Jubilant Pharma, will be receiving financing package from IFC, a member of the World Bank Group.  IFC is lending $147.5 million to Jubilant Pharma to enable better access to quality and affordable pharmaceuticals in underserved markets in India and across the world. Jubilant Pharma is incorporated in Singapore, with manufacturing operations in India, USA, and Canada. Of the total financing package, $110 million is from IFC’s own account. The remaining $37.5 million is from IFC’s Managed Co-Lending Portfolio Program, which provides additional long-term financing through co-financing partners. The loan will help Jubilant Life Sciences increase focus on the pharmaceutical sector and strengthen its generic drug manufacturing facilities in India. Jubilant Life Sciences is a pharmaceutical and life sciences company engaged in the manufacture and supply of active pharmaceutical ingredients, generics, specialty pharmaceuticals, and life science ingredients. It provides services in contract manufacturing and drug discovery and development.